<DOC>
	<DOCNO>NCT00160563</DOCNO>
	<brief_summary>Prolongation EPAACâ„¢ trial - NCT00152464 ( The Early Prevention Asthma Atopic Children ) . 36 month study evaluate efficacy safety levocetirizine ( LCTZ ) prevent onset asthma young atopic child .</brief_summary>
	<brief_title>Prevention Asthma With Levocetirizine ( 36 Month Treatment ) Young Children Suffering From Eczema ( Atopic Dermatitis ) Sensitized Grass Pollen House Dust Mite Having Completed Previous EPAAC Trial ( NCT00152464 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Inclusion criterion must verify end first 18months treatment ( Visit 9 ) Having complete previous 18month treatment period EPAAC trial NCT00152464</criteria>
	<gender>All</gender>
	<minimum_age>30 Months</minimum_age>
	<maximum_age>42 Months</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Pediatry</keyword>
	<keyword>EPAAC</keyword>
	<keyword>atopic Children</keyword>
	<keyword>prevention asthma</keyword>
	<keyword>Levocetirizine</keyword>
	<keyword>Xyzal</keyword>
</DOC>